The Palbociclib Ongoing Trials in the Management of Breast Cancer (PALOMA)-2 and PALOMA-3 phase III trials showed that palbociclib combined with endocrine therapy resulted in almost twice the PFS compared with endocrine monotherapy in patients with HR-positive/HER2-negative ABC [4,5]. The gene discussed is ERBB2; the disease is breast cancer.